highly pathogenic avian influenza vaccine

The **HPAI vaccine** is a preclinical-stage viral vector-based vaccine candidate developed by **VaxThera** in collaboration with the **University of Wisconsin**. It is designed to provide protection against **highly pathogenic avian influenza (HPAI)**, a severe viral disease caused by H5Nx subtypes (such as H5N1 and H5N8) that primarily affects poultry but poses a significant zoonotic threat to humans and other mammals. The vaccine utilizes a viral vector platform to deliver the **hemagglutinin (HA)** protein, the primary surface antigen of the influenza virus, to stimulate a robust humoral and cellular immune response. This program aims to address the critical need for effective intervention strategies in both agricultural and public health contexts, particularly for protecting poultry flocks and preventing potential pandemic spillover events.

Other names

HPAI vaccineHighly pathogenic avian influenza vaccineInfluenza aviar altamente patogénica vaccine